Mian AA, Haberbosch I, Khamaisie H, Agbarya A, et al. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K). Ann Hematol 2021;100:2023-2029.
PMID: 34110462